Who it affects: While melanoma can affect anyone, snowflake melanoma is most commonly diagnosed in adults between 40–70 years old. Men are slightly more likely than women to develop this subtype, and it occurs more frequently in individuals with fair skin, many moles, or a family history of skin cancer.

Prevalence: Snowflake melanoma accounts for roughly 2–4 % of all melanoma cases worldwide.¹ In the United States, an estimated 1,000–1,500 new cases are diagnosed each year, representing a small fraction of the ~106,000 new melanoma diagnoses reported in 2023.²

Symptoms

Because of its mixed pigmentation, snowflake melanoma can be harder to recognize than typical dark melanomas. The following signs should raise suspicion:

• Asymmetric shape – one half of the lesion looks different from the other.
• Irregular, jagged borders – edges are not smooth or well‑defined.
• Color variation – combination of dark brown/black, pink, red, blue, white, or “snow‑flake” speckles.
• Diameter greater than 6 mm (about the size of a pencil eraser), though some may be smaller.
• Evolving lesion – any change in size, shape, color, or sensation over weeks to months.
• Surface changes – ulceration, crusting, bleeding, or oozing.
• Symptoms – itching, tenderness, or a burning sensation.
• Rapid growth – some snowflake melanomas enlarge quickly, especially in the first few months.

Applying the ABCDE rule (Asymmetry, Border, Color, Diameter, Evolving) is an effective screening tool, but remember that “A” for “Amelanotic” (lack of pigment) is a key feature of this subtype.

Causes and Risk Factors

Melanoma, including the snowflake variant, arises from genetic mutations in melanocytes (the skin’s pigment‑producing cells). The exact cause of the speckled appearance is not fully understood, but research points to a combination of UV‑induced DNA damage and inherent genetic susceptibility.

Primary causes

• Ultraviolet (UV) radiation – both chronic sun exposure and intermittent intense exposure (sunburns) cause DNA breaks in melanocytes.
• Genetic mutations – alterations in the BRAF, NRAS, and c‑KIT genes are frequently found in melanoma; snowflake lesions often harbor BRAF V600E mutations.
• Immune system suppression – organ‑transplant patients, HIV infection, or long‑term immunosuppressive therapy increase risk.

Risk factors

• Fair skin, red or blond hair, blue/green eyes.
• History of severe sunburns, especially before age 18.
• Numerous atypical moles or congenital nevi.
• Family history of melanoma or known genetic syndromes (e.g., CDKN2A mutation).
• Living at high latitudes with strong UV index.
• Personal history of non‑melanoma skin cancers.
• Chronic exposure to tanning beds.

Diagnosis

Early detection relies on a thorough skin examination by a clinician. Because snowflake melanoma may look benign, a low threshold for biopsy is essential.

Clinical evaluation

• Dermoscopic examination – handheld dermatoscopes reveal characteristic patterns such as irregular globules mixed with white “snow‑flake” structures.
• Visual inspection – ABCDE criteria plus assessment for amelanotic areas.

Biopsy techniques

1. Excisional biopsy – complete removal of the lesion with a narrow margin (1–2 mm) – preferred for most suspected melanomas.
2. Punch or shave biopsy – used when the lesion is large or in a difficult location; however, it may underestimate depth.

Pathology

Histopathology confirms melanoma and determines the Breslow thickness (depth in millimeters), ulceration status, and mitotic rate—key prognostic factors. Immunohistochemical stains (e.g., S‑100, HMB‑45, Melan‑A) help differentiate melanoma from other skin tumors.

Staging investigations (if invasive)

• Sentinel lymph node biopsy (SLNB) for tumors >0.8 mm thickness or with high‑risk features.
• Imaging (CT, PET/CT, or MRI) if there are signs of regional or distant spread.
• Blood tests (LDH, CBC) for baseline health assessment.

Treatment Options

Treatment is individualized based on tumor thickness, location, and whether it has spread.

Localized disease (Stage 0‑I)

• Wide local excision – removal of the tumor with 1‑2 cm margins (depending on Breslow depth) plus a safety margin of normal skin.
• Reconstruction – skin grafts, local flaps, or primary closure as needed for cosmetic and functional outcomes.

Regional disease (Stage II‑III)

• Sentinel lymph node biopsy – if positive, completion lymph node dissection may be considered.
• Adjuvant therapy – recommended for high‑risk patients:
  • Immune checkpoint inhibitors (e.g., nivolumab, pembrolizumab).
  • Targeted therapy for BRAF‑mutated tumors (e.g., dabrafenib + trametinib).
  • Interferon‑α (less commonly used now).

Distant/metastatic disease (Stage IV)

• Systemic immunotherapy – PD‑1 inhibitors (nivolumab, pembrolizumab) ± CTLA‑4 inhibitor (ipilimumab).
• Targeted therapy – BRAF/MEK inhibitor combinations for BRAF‑mutant melanoma.
• Clinical trials – enrollment in ongoing studies can provide access to novel agents.
• Palliative radiation – for symptomatic brain or bone metastases.

Lifestyle & supportive measures

• Sun‑protective clothing and broad‑spectrum sunscreen (SPF 30+).
• Regular skin self‑exams and dermatology follow‑up.
• Psychological support – counseling or support groups (e.g., Melanoma Patient Network).
• Nutrition – a balanced diet rich in antioxidants may aid overall health, though it does not replace medical therapy.

Living with Snowflake Melanoma

Even after successful treatment, ongoing vigilance is crucial.

Surveillance schedule

• First year: full‑body skin exam every 3–4 months.
• Years 2‑5: exams every 6 months.
• After 5 years: annual visits (more frequent if high‑risk features persist).
• Imaging per oncologist’s recommendation, especially if prior nodal involvement.

Practical daily tips

• Sun protection – apply sunscreen 15 minutes before exposure; reapply every 2 hours, or after swimming/sweating.
• Self‑examination – use a full‑length mirror and a hand mirror; look for new or changing spots.
• Clothing – wear UPF‑rated shirts, wide‑brimmed hats, and UV‑protective sunglasses.
• Stay hydrated and maintain skin health – moisturize to prevent dryness that can obscure lesion evaluation.
• Document lesions – photograph moles annually for comparison.
• Medication adherence – never skip doses of adjuvant therapy; set reminders.

Emotional wellbeing

Feeling anxious or depressed after a cancer diagnosis is common. Access mental‑health resources, talk therapy, or peer‑support networks. The American Cancer Society offers free counseling hotlines.

Prevention

While genetics cannot be changed, most risk can be mitigated through UV avoidance and regular monitoring.

• UV protection – use SPF 30+ sunscreen, seek shade between 10 a.m. and 4 p.m., avoid tanning beds.
• Skin checks – annual dermatologist exams, especially for those with a personal/family melanoma history.
• Protective clothing – long sleeves, pants, and wide‑brimmed hats.
• Vitamin D balance – limited sun exposure may affect vitamin D; discuss supplementation with your physician.
• Healthy lifestyle – regular exercise and a diet rich in fruits, vegetables, and omega‑3 fatty acids support immune function.

Complications

If left untreated or inadequately managed, snowflake melanoma can lead to serious outcomes:

• Local invasion – ulceration, infection, or involvement of underlying muscle/bone.
• Lymph node metastasis – spread to regional nodes, increasing recurrence risk.
• Distant metastasis – to lungs, liver, brain, or bone, markedly reducing survival.
• Secondary skin cancers – patients with melanoma have higher odds of developing basal cell or squamous cell carcinoma.
• Psychosocial impact – anxiety, body‑image concerns, and reduced quality of life.

Five‑year survival for localized melanoma exceeds 98 %, but drops to ~23 % for distant metastatic disease.²

When to Seek Emergency Care

References

1. American Academy of Dermatology. Melanoma Subtypes and Variants. 2023. Available at: aad.org
2. American Cancer Society. Key Statistics for Melanoma Skin Cancer. 2024. Available at: cancer.org
3. Mayo Clinic. Melanoma – Symptoms and causes. Updated 2023. mayoclinic.org
4. National Cancer Institute. Melanoma Treatment (PDQ®)–Health Professional Version. 2024. cancer.gov
5. World Health Organization. Cancer fact sheets – Skin cancers. 2022. who.int